Engineered exosomes - Capricor Therapeutics
Alternative Names: Cardiosphere-Derived Exosomes; CDC-EVsLatest Information Update: 28 Sep 2025
At a glance
- Originator Capricor Therapeutics
- Developer Capricor Therapeutics; US Army Institute of Surgical Research
- Class Exosome therapies; MicroRNAs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haemorrhagic shock; Traumatic brain haemorrhage
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Haemorrhagic shock in USA (Parenteral)
- 28 Sep 2025 No recent reports of development identified for preclinical development in Traumatic-brain-haemorrhage in USA (Parenteral)
- 04 Aug 2021 Preclinical trials in Haemorrhagic shock in USA (Parenteral)